Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.76
EXAS's Cash-to-Debt is ranked higher than
67% of the 261 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.52 vs. EXAS: 1.76 )
Ranked among companies with meaningful Cash-to-Debt only.
EXAS' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.76  Med: No Debt Max: No Debt
Current: 1.76
1.76
No Debt
Equity-to-Asset 0.48
EXAS's Equity-to-Asset is ranked higher than
90% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. EXAS: 0.48 )
Ranked among companies with meaningful Equity-to-Asset only.
EXAS' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.41  Med: 0.75 Max: 0.96
Current: 0.48
-0.41
0.96
Debt-to-Equity 0.94
EXAS's Debt-to-Equity is ranked higher than
99% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.36 vs. EXAS: 0.94 )
Ranked among companies with meaningful Debt-to-Equity only.
EXAS' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01  Med: 0.01 Max: 0.94
Current: 0.94
0.01
0.94
Debt-to-EBITDA -6.99
EXAS's Debt-to-EBITDA is ranked lower than
99.99% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.77 vs. EXAS: -6.99 )
Ranked among companies with meaningful Debt-to-EBITDA only.
EXAS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.22  Med: -0.04 Max: -0.01
Current: -6.99
-0.22
-0.01
Piotroski F-Score: 5
Altman Z-Score: 6.39
Beneish M-Score: -3.59
WACC vs ROIC
21.68%
-97.08%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -33.36
EXAS's Operating Margin % is ranked lower than
66% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.59 vs. EXAS: -33.36 )
Ranked among companies with meaningful Operating Margin % only.
EXAS' s Operating Margin % Range Over the Past 10 Years
Min: -5589.32  Med: -312.12 Max: 1080.85
Current: -33.36
-5589.32
1080.85
Net Margin % -35.83
EXAS's Net Margin % is ranked lower than
65% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.48 vs. EXAS: -35.83 )
Ranked among companies with meaningful Net Margin % only.
EXAS' s Net Margin % Range Over the Past 10 Years
Min: -5564.4  Med: -307.98 Max: 1123.53
Current: -35.83
-5564.4
1123.53
ROE % -22.36
EXAS's ROE % is ranked lower than
61% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.75 vs. EXAS: -22.36 )
Ranked among companies with meaningful ROE % only.
EXAS' s ROE % Range Over the Past 10 Years
Min: -505.37  Med: -48.84 Max: -26.74
Current: -22.36
-505.37
-26.74
ROA % -13.15
EXAS's ROA % is ranked lower than
62% of the 262 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.54 vs. EXAS: -13.15 )
Ranked among companies with meaningful ROA % only.
EXAS' s ROA % Range Over the Past 10 Years
Min: -95.07  Med: -44.39 Max: -18.86
Current: -13.15
-95.07
-18.86
ROC (Joel Greenblatt) % -99.75
EXAS's ROC (Joel Greenblatt) % is ranked lower than
68% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -9.57 vs. EXAS: -99.75 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
EXAS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3464.42  Med: -1165.99 Max: -193.65
Current: -99.75
-3464.42
-193.65
3-Year Revenue Growth Rate 371.00
EXAS's 3-Year Revenue Growth Rate is ranked higher than
99% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. EXAS: 371.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
EXAS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -17.6 Max: 371
Current: 371
0
371
3-Year EBITDA Growth Rate 10.70
EXAS's 3-Year EBITDA Growth Rate is ranked higher than
52% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. EXAS: 10.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
EXAS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -46.2  Med: 11.2 Max: 39.4
Current: 10.7
-46.2
39.4
3-Year EPS without NRI Growth Rate 7.50
EXAS's 3-Year EPS without NRI Growth Rate is ranked lower than
56% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. EXAS: 7.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
EXAS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -46.5  Med: 13.2 Max: 43.1
Current: 7.5
-46.5
43.1
GuruFocus has detected 1 Warning Sign with Exact Sciences Corp EXAS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» EXAS's 30-Y Financials

Financials (Next Earnings Date: 2019-02-21 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2017

EXAS Guru Trades in Q4 2017

Steven Cohen 546,806 sh (New)
Paul Tudor Jones 5,357 sh (New)
Ken Fisher 6,350 sh (unchged)
Jim Simons Sold Out
Columbia Wanger Sold Out
Joel Greenblatt 215,037 sh (-36.18%)
PRIMECAP Management 3,579,100 sh (-13.48%)
Pioneer Investments 359,911 sh (-21.45%)
» More
Q1 2018

EXAS Guru Trades in Q1 2018

Steve Mandel 1,298,001 sh (New)
John Hussman 75,000 sh (New)
Steven Cohen 576,800 sh (+5.49%)
Paul Tudor Jones 25,183 sh (+370.10%)
Pioneer Investments 420,610 sh (+16.87%)
PRIMECAP Management 3,579,100 sh (unchged)
Ken Fisher Sold Out
Joel Greenblatt 128,614 sh (-40.19%)
» More
Q2 2018

EXAS Guru Trades in Q2 2018

Ken Fisher 55,621 sh (New)
Jim Simons 86,300 sh (New)
Paul Tudor Jones 76,583 sh (+204.11%)
Pioneer Investments 425,731 sh (+1.22%)
PRIMECAP Management 3,579,100 sh (unchged)
Steve Mandel Sold Out
Steven Cohen Sold Out
Joel Greenblatt 92,142 sh (-28.36%)
John Hussman 25,000 sh (-66.67%)
» More
Q3 2018

EXAS Guru Trades in Q3 2018

Eaton Vance Worldwide Health Sciences Fund 53,522 sh (New)
Andreas Halvorsen 1,294,650 sh (New)
Jana Partners 1,163,513 sh (New)
Ken Fisher 56,051 sh (+0.77%)
Jim Simons 249,198 sh (+188.76%)
Pioneer Investments 476,772 sh (+11.99%)
PRIMECAP Management 3,579,100 sh (unchged)
Paul Tudor Jones Sold Out
John Hussman 20,000 sh (-20.00%)
Joel Greenblatt 43,826 sh (-52.44%)
» More
» Details

Insider Trades

Latest Guru Trades with EXAS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Exact Sciences Corp does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 8731
Compare:NAS:ICLR, XTER:AFX, NAS:DXCM, NAS:PRAH, MIL:DIA, NYSE:QGEN, NYSE:CRL, NYSE:BIO, NAS:BRKR, NYSE:PKI, SHSE:603658, NAS:SYNH, NAS:NEOG, XPAR:ERF, XPAR:BIM, SZSE:300676, NAS:FMI, XTER:SRT3, BSP:DASA3, BSP:FLRY3 » details
Traded in other countries:EXK.Germany,
Headquarter Location:USA
Exact Sciences Corp operates in the healthcare sector. It is a diagnostics company focused on the early detection and prevention of colorectal cancer.

Exact Sciences is a molecular diagnostics company focused on the early detection and prevention of certain types of cancer. Its core product is a noninvasive screening test, Cologuard, which analyzes stool-based DNA samples to detect the precancerous and early stages of colorectal cancer. The test includes DNA markers and a protein marker that can detect blood in the stool. Exact Sciences receives revenue from two sources: laboratory services and licensing fees. Its laboratory services revenue is generated by diagnostic services that use the Cologuard test. Exact Sciences also receives revenue from the licensing of its product rights.

Guru Investment Theses on Exact Sciences Corp

Meridian Funds Comments on Exact Sciences Corp - May 18, 2017

Exact Sciences Corp. (NASDAQ:EXAS) develops noninvasive molecular screening tests for the early detection and prevention of colorectal cancer. We originally invested in the company because Cologuard, its revolutionary product, exhibited low market penetration and significant opportunity for continued adoption. Test accuracy versus other non-invasive tests has led to improved adoption rates and recent annual revenue growth in excess of 150%. Large commercial insurer, Aetna, recently announced its decision to cover the screening for qualified members. In this positive environment, Exact Sciences raised its test volume expectations to 415,000 for the year and noted meaningful gross margin improvement as its business model continues to scale faster than expected. As such, we are maintaining our position.



From Meridian Growth Funds first-quarter 2017 shareholder commentary.



Check out Meridian Funds latest stock trades

Ratios

vs
industry
vs
history
PB Ratio 11.71
EXAS's PB Ratio is ranked lower than
85% of the 245 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.02 vs. EXAS: 11.71 )
Ranked among companies with meaningful PB Ratio only.
EXAS' s PB Ratio Range Over the Past 10 Years
Min: 1.69  Med: 7.79 Max: 36.44
Current: 11.71
1.69
36.44
PS Ratio 20.82
EXAS's PS Ratio is ranked lower than
86% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.81 vs. EXAS: 20.82 )
Ranked among companies with meaningful PS Ratio only.
EXAS' s PS Ratio Range Over the Past 10 Years
Min: 10.55  Med: 46.49 Max: 1325.45
Current: 20.82
10.55
1325.45
EV-to-EBIT -67.41
EXAS's EV-to-EBIT is ranked lower than
99.99% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.06 vs. EXAS: -67.41 )
Ranked among companies with meaningful EV-to-EBIT only.
EXAS' s EV-to-EBIT Range Over the Past 10 Years
Min: -78.4  Med: -13.85 Max: -0.4
Current: -67.41
-78.4
-0.4
EV-to-EBITDA -81.83
EXAS's EV-to-EBITDA is ranked lower than
99.99% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.75 vs. EXAS: -81.83 )
Ranked among companies with meaningful EV-to-EBITDA only.
EXAS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -95.2  Med: -14.3 Max: -0.5
Current: -81.83
-95.2
-0.5
EV-to-Revenue 19.76
EXAS's EV-to-Revenue is ranked lower than
84% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.24 vs. EXAS: 19.76 )
Ranked among companies with meaningful EV-to-Revenue only.
EXAS' s EV-to-Revenue Range Over the Past 10 Years
Min: 4.3  Med: 38 Max: 1390.2
Current: 19.76
4.3
1390.2
Current Ratio 12.08
EXAS's Current Ratio is ranked higher than
87% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.58 vs. EXAS: 12.08 )
Ranked among companies with meaningful Current Ratio only.
EXAS' s Current Ratio Range Over the Past 10 Years
Min: 1.02  Med: 9.49 Max: 50.84
Current: 12.08
1.02
50.84
Quick Ratio 11.72
EXAS's Quick Ratio is ranked higher than
86% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. EXAS: 11.72 )
Ranked among companies with meaningful Quick Ratio only.
EXAS' s Quick Ratio Range Over the Past 10 Years
Min: 1.02  Med: 9.49 Max: 50.84
Current: 11.72
1.02
50.84
Days Inventory 106.35
EXAS's Days Inventory is ranked higher than
55% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.76 vs. EXAS: 106.35 )
Ranked among companies with meaningful Days Inventory only.
EXAS' s Days Inventory Range Over the Past 10 Years
Min: 54.55  Med: 77.69 Max: 169.5
Current: 106.35
54.55
169.5
Days Sales Outstanding 38.36
EXAS's Days Sales Outstanding is ranked higher than
83% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.51 vs. EXAS: 38.36 )
Ranked among companies with meaningful Days Sales Outstanding only.
EXAS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 31.32  Med: 40.96 Max: 279.33
Current: 38.36
31.32
279.33
Days Payable 115.68
EXAS's Days Payable is ranked higher than
59% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. EXAS: 115.68 )
Ranked among companies with meaningful Days Payable only.
EXAS' s Days Payable Range Over the Past 10 Years
Min: 5.73  Med: 1526.07 Max: 249295
Current: 115.68
5.73
249295

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -10.80
EXAS's 3-Year Average Share Buyback Ratio is ranked lower than
59% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.90 vs. EXAS: -10.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
EXAS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -217.1  Med: -11.9 Max: -1
Current: -10.8
-217.1
-1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 21.41
EXAS's Price-to-Net-Cash is ranked lower than
59% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.60 vs. EXAS: 21.41 )
Ranked among companies with meaningful Price-to-Net-Cash only.
EXAS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.02  Med: 6.74 Max: 90
Current: 21.41
2.02
90
Price-to-Net-Current-Asset-Value 16.90
EXAS's Price-to-Net-Current-Asset-Value is ranked lower than
69% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.88 vs. EXAS: 16.90 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
EXAS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.98  Med: 6.57 Max: 60
Current: 16.9
1.98
60
Price-to-Tangible-Book 12.09
EXAS's Price-to-Tangible-Book is ranked lower than
74% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.46 vs. EXAS: 12.09 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
EXAS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.87  Med: 6.29 Max: 33.71
Current: 12.09
1.87
33.71
Price-to-Median-PS-Value 0.45
EXAS's Price-to-Median-PS-Value is ranked higher than
83% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. EXAS: 0.45 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
EXAS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.24  Med: 0.97 Max: 185.2
Current: 0.45
0.24
185.2
Earnings Yield (Greenblatt) % -1.48
EXAS's Earnings Yield (Greenblatt) % is ranked lower than
52% of the 265 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.98 vs. EXAS: -1.48 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
EXAS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -275  Med: -7.2 Max: -1.3
Current: -1.48
-275
-1.3

More Statistics

Revenue (TTM) (Mil) $398.89
EPS (TTM) $ -1.18
Beta3.13
Volatility49.03%
52-Week Range $37.36 - 82.85
Shares Outstanding (Mil)122.90

Analyst Estimate

Dec18 Dec19 Dec20 Dec21
Revenue (Mil $) 438 711 1,027 1,250
EBIT (Mil $) -167 -62 59
EBITDA (Mil $) -141 -3 129
EPS ($) -1.52 -0.95 0.17 1.40
EPS without NRI ($) -1.52 -0.95 0.17 1.40
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}